1147077-80-2Relevant academic research and scientific papers
Design and characterization of optimized adenosine A2A/A 1 receptor antagonists for the treatment of Parkinson's disease
Shook, Brian C.,Rassnick, Stefanie,Wallace, Nathaniel,Crooke, Jeffrey,Ault, Mark,Chakravarty, Devraj,Barbay, J. Kent,Wang, Aihua,Powell, Mark T.,Leonard, Kristi,Alford, Vernon,Scannevin, Robert H.,Carroll, Karen,Lampron, Lisa,Westover, Lori,Lim, Heng-Keang,Russell, Ronald,Branum, Shawn,Wells, Kenneth M.,Damon, Sandra,Youells, Scott,Li, Xun,Beauchamp, Derek A.,Rhodes, Kenneth,Jackson, Paul F.
, p. 1402 - 1417 (2012/04/04)
The design and characterization of two, dual adenosine A 2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential treatment for Parkinson's disease. Fu
Optimization of arylindenopyrimidines as potent adenosine A2A/A1 antagonists
Shook, Brian C.,Rassnick, Stefanie,Chakravarty, Devraj,Wallace, Nathaniel,Ault, Mark,Crooke, Jeffrey,Barbay, J. Kent,Wang, Aihua,Leonard, Kristi,Powell, Mark T.,Alford, Vernon,Hall, Daniel,Rupert, Kenneth C.,Heintzelman, Geoffrey R.,Hansen, Kristen,Bullington, James L.,Scannevin, Robert H.,Carroll, Karen,Lampron, Lisa,Westover, Lori,Russell, Ronald,Branum, Shawn,Wells, Kenneth,Damon, Sandra,Youells, Scott,Beauchamp, Derek,Li, Xun,Rhodes, Kenneth,Jackson, Paul F.
scheme or table, p. 2868 - 2871 (2010/07/06)
Two reactive metabolites were identified in vivo for the dual A2A/A1 receptor antagonist 1. Two strategies were implemented to successfully mitigate the metabolic liabilities associated with 1. Optimization of the arylindenopyrimidines led to a number of amide, ether, and amino analogs having comparable in vitro and in vivo activity.
ARYLINDENOPYRIMIDINES COMPOUND AND USE AS AN ADENOSINE A2a RECEPTOR ANTAGONISTS
-
Page/Page column 3; 4, (2009/05/29)
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease.
